Alvotech
Officers & Directors
Robert Wessman, age 56, is the Chief Executive Officer and Executive Chairman of the Board of Directors of Alvotech. He founded the company and has held executive roles at Fuji Pharma, Lotus Pharmaceuticals, Aztiq, Alvogen, and Actavis. He holds a Bachelor of Science degree in Business Administration from the University of Iceland. Tanya Zharov, age 59, serves as General Counsel and previously was Deputy Chief Executive Officer at Alvotech. Her prior management experience includes positions at deCODE genetics, Virding hf, Audur Capital, and PricewaterhouseCoopers. She holds a law degree from the University of Iceland and is a European Patent Attorney. Joseph E. McClellan, age 52, is Chief Operating Officer and has been Chief Scientific Officer since 2019. He worked at Pfizer Inc. for over 17 years and holds a PhD in Chemistry from the University of Florida. Linda Jónsdóttir, age 48, has been Chief Financial Officer since July 2025. She previously held senior roles at Marel and worked at Sidekick Health, Eimskip, Burdaras, and Straumur investment bank. She holds a Cand. Oecon degree in Finance and a Master in Corporate Finance from Reykjavik University.
Alvotech currently has 1460 employees.
News about Alvotech Key Personnel |
In recent news, Alvotech, a renowned global biotech company specializing in biosimilar medicines, has announced its active participation in the highly anticipated BofA Securities Healthcare Conference 2024. The conference, scheduled to take place on May 14-15, 2024, in Las Vegas, NV, will be a significant platform for Alvotech to showcase its expertise and reinforce its position as a key player in the industry.
Alvotech s presence at the BofA Securities Healthcare Conference 2024 reflects the company s commitment to innovation and its dedication to providing affordable and accessible biosimilar medicines for patients worldwide. With the global biotech market rapidly expanding, such conferences serve...
|
|
